Scarica l'app Stockscreener
3.57
0.28%
0.010
Pre-mercato:
3.70
0.13
+3.64%
Precedente Chiudi:
$3.56
Aprire:
$3.56
Volume 24 ore:
405.01K
Relative Volume:
0.47
Capitalizzazione di mercato:
$272.98M
Reddito:
$114.70K
Utile/perdita netta:
$-26.49M
Rapporto P/E:
-1.4474
EPS:
-2.4665
Flusso di cassa netto:
$-53.17M
1 W Prestazione:
+1.71%
1M Prestazione:
-8.46%
6M Prestazione:
-18.68%
1 anno Prestazione:
+89.89%
Intervallo 1D:
$3.42
$3.58
Intervallo di 1 settimana:
$3.35
$3.635
Portata 52W:
$1.85
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.57 | 263.04M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-02 | Iniziato | Rodman & Renshaw | Buy |
| 2025-12-19 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Iniziato | Leerink Partners | Outperform |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW - TradingView
SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support LevelsPositive Gamma - dars.gov.et
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS - MarketBeat
SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support LevelsCorrective Wave - DonanımHaber
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks
Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart
Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView
Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - The Manila Times
Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance
SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et
Barclays Initiates Overweight Rating on SAB Biotherapeutics, Signaling Positive Sector SentimentGross Profit Margin - dars.gov.et
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS) - TradingView
SABS Forecast — Price Target — Prediction for 2027 - TradingView
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com
SABS Q1 2026 Earnings: EPS Misses Estimates as Operational Costs ClimbEPS Estimate Trend - dars.gov.et
Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart
SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sab Biotherapeutics Inc Azioni (SABS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):